Liposomal amphotericin B related late-onset hyperphosphatemia in a pediatric patient with acute myeloid leukemia
- Resource Type
- Authors
- Sude Ayça Çifci; Nadir Yalçın; Tekin Aksu; Kutay Demirkan
- Source
- Journal of Oncology Pharmacy Practice. 28:1478-1482
- Subject
- Hyperphosphatemia
Leukemia, Myeloid, Acute
Antifungal Agents
Oncology
Amphotericin B
Humans
Pharmacology (medical)
Child
- Language
- ISSN
- 1477-092X
1078-1552
Introduction Children with acute myeloid leukemia (AML) are at risk for serious electrolyte abnormalities. Case report We reported a case of hyperphosphatemia in a child with acute myeloid leukemia who received liposomal amphotericin B (AMBL) for the treatment of an invasive fungal infection. The findings of this case suggest that cumulative dose accumulation due to long term AMBL treatment may result in late-onset hyperphosphatemia. Management and outcome This is the first case report in the literature that of late-onset hyperphosphatemia (day 56) in a patient with low-dose AMBL treatment (3–5 mg/kg/day) and normal renal function. Discussion We highlight the importance of increasing awareness of AMBL related hyperphosphatemia among healthcare providers.